**GRADE TABLE 3**

**Population:** Pregnant women.

**Intervention:** Tetanus Toxoid Containing Vaccine (TTCV).

**Comparison:** No vaccination or control.

**Outcome:** Serious adverse events following immunization.

<table>
<thead>
<tr>
<th>PICO Question: Is the incidence of serious adverse events in pregnant women with any dose of TTCV vaccine rare when compared to not giving the vaccine?</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image-url" alt="Image of GRADE table 3" /></td>
</tr>
</tbody>
</table>

---

**Summary of Findings**

**Statement on certainty of evidence**

Evidence from one RCT supports a moderate level of confidence that the true effect lies close to that of the estimate of the effect on the health outcome. This evidence is supported by the fact that tetanus toxoid-containing vaccines have extensively been used in pregnant women for several decades without generating safety signals, including analyses from data generated in observational studies [3,4].

**Conclusion**

TTCV using various presentations have demonstrated to be safe for use in pregnant women and there is no evidence of adverse pregnancy outcomes.3

---

1 From Demicheli et al. [1] 1 randomized controlled trial was identified [2] evaluating the safety of Tdap immunization during pregnancy. No Tdap-associated serious adverse events occurred in women or infants.

2 A downgrading was performed since the RCT [2] did not have sufficient power to detect rare serious adverse events.

3 Supporting evidence [3] includes a hospital-based case-control study that evaluated the safety of TT in pregnant women related to congenital abnormalities. There was no difference between the groups on infants whose mothers were exposure to TT and those who were not exposed on the rates of common congenital anomalies.
References

